EGFR TKIs impair lysosome-dependent degradation of SQSTM1 to compromise the effectiveness in lung cancer

Tyrosine kinase inhibitors for epidermal growth factor receptor (EGFR TKIs) greatly improved clinical outcomes of patients with non-small cell lung cancer (NSCLC). Unfortunately, primary and acquired resistance limits their clinical benefits. To overcome such resistance, new generations of EGFR TKIs...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Signal Transduct Target Ther
Main Authors: Yang, Lixian, Ying, Shilong, Hu, Shiman, Zhao, Xiangtong, Li, Muchun, Chen, Miaoqin, Zhu, Yiran, Song, Ping, Zhu, Liyuan, Jiang, Tingting, An, Huimin, Yousafzai, Neelum Aziz, Xu, Wenxia, Zhang, Zhiguo, Wang, Xian, Feng, Lifeng, Jin, Hongchuan
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2019
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6799834/
https://ncbi.nlm.nih.gov/pubmed/31637005
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41392-019-0059-4
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki